Your AI-Trained Oncology Knowledge Connection!
A urine assay that targets expression of exosomal messenger RNA demonstrated high negative predictive value for high-grade prostate cancer in a study that validates the emerging test as a tool to help determine whether patients need initial biopsies.
Enzalutamide significantly improved progression-free survival, PSA kinetics, and quality of life compared with bicalutamide in men with castration-resistant prostate cancer.
Kyle A. Richards, MD, assistant professor, University of Wisconsin, discusses the association between urinary tract infections (UTI) and worse bladder cancer outcomes in the Medicare population.
Michael Brawer, MD, vice president of Medical Affairs, Myriad Genetic Laboratories, discusses the clinical utility of the cell cycle progression (CCP) test in personalizing prostate cancer treatment.
As the AS strategy gains a foothold among urologists both here in the US and around the world, a study presented at the 110th Annual Scientific Meeting of the American Urological Association suggests that among men in the US, very few are following the stringent protocol for AS that is recommended by major academic institutions.
Use of multiparametric MRI as follow-up to a suggestive PSA test or digital rectal exam reduced prostate biopsies by 73% but identified fewer prostate cancers compared with upfront transrectal ultrasound–guided biopsy, a decision-tree analysis showed.
The role of androgen receptor variant-7 in patients with early stage prostate cancer is not well characterized but data presented at the 2015 American Urological Association (AUA) Meeting is bringing the discussion into focus.
Alexander Kutikov, MD, FACS, attending surgeon, urologic oncology, associate professor, urologic oncology, Fox Chase Cancer Center, discusses the understanding of tumor pathology in renal cell carcinoma.
E. David Crawford, MD, professor, urology, radiation oncology, University of Colorado Denver, discusses the differences between an LHRH agonist and a GNRH antagonist.
Adding elotuzumab to lenalidomide (Revlimid) and dexamethasone reduced the risk of disease progression by 30% in patients with relapsed/refractory multiple myeloma.
The addition of docetaxel to standard hormonal therapy significantly improved survival among men with newly diagnosed, hormone-naïve advanced prostate cancer.
For those with a history of non-melanoma skin cancer, reducing their risk of recurrence can be as simple as taking the vitamin B3 pill nicotinamide.
Treatment with an intensified chemotherapy regimen was associated with improvements in event-free survival for children with favorable histology Wilms tumor with loss of heterozygosity in chromosomes 1p and 16q.
Guillermo Garcia-Manero, MD, chief, Section of Myelodysplastic Syndromes, deputy chair, Translational Research, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses deferasirox (Exjade) in iron chelation therapy for patients with myelodysplastic syndromes (MDS).
Treatment with the thrombopoietin receptor agonist eltrombopag significantly improved cytopenias and was well-tolerated in patients with low to intermediate-2 risk myelodysplastic syndromes.
A biomarker model that incorporates the mutational status of multiple somatic genes could be used to predict response to hypomethylating agents for patients with myelodysplastic syndromes.
Serum erythropoietin levels and risk by IPSS were predictive of response to erythropoiesis-stimulating agents in patients with myelodysplastic syndromes.
Gail J. Roboz, MD, associate professor of Medicine, director, Leukemia Program, Weill Medical College of Cornell University, New York-Presbyterian Hospital, discusses the growing field of molecular mutations in myelodysplastic syndromes (MDS).
Amer Zeidan, MBBS, MHS, assistant professor of Medicine, Hematology, Yale Cancer Center, discusses a population-based study of subsequent myelodysplastic syndromes (MDS) in prostate cancer patients after radiotherapy.
Treatment with T-cell depleted transplantation was associated with a lower incidence of acute graft versus host disease (GVHD) and a very low incidence of chronic GVHD compared with unmodified allografts in patients with advanced myelodysplastic syndrome.
Treatment with lenalidomide (Revlimid) versus placebo improved health-related quality of life (HRQoL) after 24 weeks for patients with myelodysplastic syndromes.
Treatment strategies for patients with myelodysplastic syndromes are built upon a foundation of supportive care, which consists of transfusions, iron chelation, and growth factor therapy.
Sara M. Tinsley, MS, PhD, ARNP, AOCN, nurse practitioner, malignant hematology, Moffitt Cancer Center, discusses a study that examined quality of life in patients with high-risk myelodysplastic syndromes (MDS).
Rami S. Komrokji, MD, clinical director, Department of Malignant Hematology, H. Lee Moffitt Cancer Center, discusses a study that examined risk stratification of therapy-related MDS.
OncLive spoke with Guillermo Garcia-Manero, MD, regarding the significance of sotatercept and rigosertib and their potential as therapies in MDS.
HLA-matched allogeneic hematopoietic stem cell transplantation was associated with more than a doubling in 4-year overall survival rates for patients with intermediate-2 or high-risk myelodysplastic syndromes.
Bart L. Scott, assistant member, clinical research division, Fred Hutchinson Cancer Research Center, discusses a new registry that will collect data from patients with MDS.
Guillermo Garcia-Manero, MD, chief, Section of Myelodysplastic Syndromes, deputy chair, Translational Research, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the multikinase inhibitor rigosertib in patients with MDS who have failed hypomethylating agents.
The first-in-class activin receptor antagonist sotatercept stimulated erythropoiesis in nearly half of patients with MDS and non-proliferative CMML following failure on erythropoiesis-stimulating agents.
Interview with Thomas Prebet MD, PhD, in advance of the 2015 International MDS Symposium, on topics related to supportive care in MDS and iron chelation therapy.
